Published in Cancer Weekly, December 17th, 2002
Bard has spent his 28-year career in the medical products industry. Most recently, he served as a corporate officer and the vice president of regulatory affairs at Gliatech, where he was responsible for strategic planning of regulatory affairs, quality assurance, and manufacturing operations.
"As CeMines continues to progress in the clinical development of its molecular fingerprinting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.